Nanjing

Researchers are investigating the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib to treat women and men with locally advanced or metastatic estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer that has an ESR1 mutation. This phase 3 study includes patients who have previously received treatment with ribociclib or palbociclib and aims to evaluate the effectiveness, safety, and tolerability of these treatment combinations. Participants will be randomly assigned to receive either oral lasofoxifene at 5 mg daily combined with oral abemaciclib 150 mg twice a day, or intramuscular fulvestrant 500 mg on specific days followed by monthly doses plus oral abemaciclib 150 mg twice daily. The treatment schedules are designed to compare how well these combinations work in managing the cancer. During the study, participants will be closely monitored for progression-free survival over approximately three years. Researchers will assess the cancer's response to treatment, track any side effects, and evaluate safety and tolerability. Regular evaluations and follow-ups will ensure comprehensive data collection to understand the impact of these therapies on advanced breast cancer.

Researchers are evaluating coronary artery bypass surgery (CABG) in patients with coronary artery disease, focusing on whether using two or more arterial grafts instead of a single arterial graft reduces the combined risk of death, stroke, heart attack, or repeat surgeries. This large, international, randomized trial aims to test if multiple arterial grafts improve long-term survival and reduce serious complications after surgery. Patients are randomly assigned to receive either a single arterial graft using the left internal thoracic artery to the main heart artery, supported by vein grafts for other blocked vessels, or multiple arterial grafts including a second arterial graft (right internal thoracic artery or radial artery) to a major heart branch plus additional vein or arterial grafts. The study enrolls at least 4,300 patients across 25 centers worldwide, with treatment randomly assigned in equal groups. Participants will be followed to measure outcomes such as death, stroke, heart attack after hospital discharge, and repeat procedures occurring more than 72 hours after surgery. The trial records health events and survival to assess differences between the two grafting approaches. This detailed monitoring helps researchers understand the benefits and risks of using multiple arterial grafts in CABG over time.